Get the Stockscreener App
0.90
61.86%
-1.46
After Hours:
.90
Lipella Pharmaceuticals Inc stock is traded at $0.90, with a volume of 19,002.
It is down -61.86% in the last 24 hours and down -68.37% over the past month.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
See More
Previous Close:
$2.36
Open:
$0.95
24h Volume:
19,002
Relative Volume:
0.26
Market Cap:
$12.87M
Revenue:
-
Net Income/Loss:
$-4.74M
P/E Ratio:
-1.20
EPS:
-0.75
Net Cash Flow:
$-3.46M
1W Performance:
-61.86%
1M Performance:
-68.37%
6M Performance:
-71.43%
1Y Performance:
-74.98%
1-Day Range:
$0.85
$1.00
1-Week Range:
$0.85
$1.00
52-Week Range:
$0.85
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-901-0315
Address
400 N LEXINGTON ST, PITTSBURGH
Compare LIPO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
0.90 | 12.87M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - GlobeNewswire
Lipella Pharmaceuticals announces U.S. patent issuance for diagnostic tech - TipRanks
New Patent Powers Lipella's Breakthrough: MRI Technology Could Transform Disease Detection Until 2045 - Stock Titan
Lipella Pharmaceuticals Announces 2025 Stockholders Meeting Date - TipRanks
LIPO Secures Continued Partnership with Cook MyoSite for Enhanced Product Development | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Inc. Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite Inc. to Support LP-310 Clinical Development - MarketScreener
Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite - Contract Pharma
Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite - TipRanks
Lipella Pharmaceuticals extends manufacturing pact with Cook MyoSite - Investing.com
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development - GlobeNewswire
First-Ever Oral Lichen Planus Treatment Advances as Lipella Secures Key Manufacturing Deal - Stock Titan
Lipella Pharmaceuticals to appeal Nasdaq noncompliance warningPittsburgh Business Times - The Business Journals
Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge - TipRanks
LIPO: Lipella Pharmaceuticals Reports Promising Phase 2a Trial Results for LP-310 | LIPO Stock News - GuruFocus
Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data - TipRanks
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 - GlobeNewswire
Breakthrough Phase 2a Data: New LP-310 Treatment Cuts Oral Lichen Planus Pain by 65%, Exceeds Endpoints - Stock Titan
Analytical Overview: Lipella Pharmaceuticals Inc (LIPO)’s Ratios Tell a Financial Story - DWinneX
Lipella Pharmaceuticals Abstract on Oral Lichen Planus - GlobeNewswire
Clinical Data: New Treatment Breakthrough for Oral Lichen PlanusPhase 2a Trial Shows Remarkable Improvement - Stock Titan
LIPO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
LIPO stock’s current quarter earnings estimates: What analysts predict? - uspostnews.com
Lipella Reports Positive Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus - Reuters
Lipella Pharmaceuticals announces results from second cohort of LP-310 trial - TipRanks
Lipella Reports Positive Phase 2a Results from Second - GlobeNewswire
Clinical Trial Breakthrough: New Oral Lichen Planus Treatment Shows 65% Pain Reduction, Multiple Endpoint Success - Stock Titan
Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis - MarketBeat
Lipella Pharmaceuticals regains Nasdaq compliance By Investing.com - Investing.com Canada
Lipella Pharmaceuticals regains Nasdaq compliance - Investing.com Australia
Lipella Pharmaceuticals expands preferred stock class - Investing.com Australia
Lipella Pharmaceuticals stock hits 52-week low at $2 By Investing.com - Investing.com Canada
Lipella Pharmaceuticals expands preferred stock class By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals stock hits 52-week low at $2 - Investing.com
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - The Manila Times
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Virtu Financial LLC Acquires Shares of 13,310 Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - The Globe and Mail
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tariffs and Tech Troubles Weigh on Markets - The Globe and Mail
Lipella Pharmaceuticals Inc. (LIPO) reports earnings - Quartz
LIPELLA PHARMACEUTICALS INC. SEC 10-K Report - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Spartan Capital Securities, LLC Proudly Serves as the Sole Agent in Lipella Pharmaceuticals Inc. - Ukraine Business Journal
Lipella Pharmaceuticals stock hits 52-week low at $2.21 - Investing.com Australia
Spartan Capital Securities, LLC Announces Key February Transactions - The Manila Times
Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewswire Inc.
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):